These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 13677570)

  • 1. Oral pharmacotherapy of childhood movement disorders.
    Edgar TS
    J Child Neurol; 2003 Sep; 18 Suppl 1():S40-9. PubMed ID: 13677570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of pediatric movement disorders.
    Sanger TD
    J Child Neurol; 2003 Sep; 18 Suppl 1():S9-24. PubMed ID: 13677568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment and treatment of movement disorders in children with cerebral palsy.
    Deon LL; Gaebler-Spira D
    Orthop Clin North Am; 2010 Oct; 41(4):507-17. PubMed ID: 20868881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Movement disorders--concept and grand classification].
    Araki S
    Nihon Rinsho; 1993 Nov; 51(11):2816-22. PubMed ID: 8277555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of spasticity in children with cerebral palsy.
    Verrotti A; Greco R; Spalice A; Chiarelli F; Iannetti P
    Pediatr Neurol; 2006 Jan; 34(1):1-6. PubMed ID: 16376270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Movement disorders in children: definitions, classifications, and grading systems.
    Delgado MR; Albright AL
    J Child Neurol; 2003 Sep; 18 Suppl 1():S1-8. PubMed ID: 13677567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hyperkinetic movement disorders.
    Jankovic J
    Lancet Neurol; 2009 Sep; 8(9):844-56. PubMed ID: 19679276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral pharmacotherapy for the movement disorders of cerebral palsy.
    Pranzatelli MR
    J Child Neurol; 1996 Nov; 11 Suppl 1():S13-22. PubMed ID: 8959457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of botulinum toxin type A with oral anti-spasticity medications in the management of focal spasticity.
    Dai A
    J Rehabil Med; 2007 Mar; 39(2):189; author reply 189. PubMed ID: 17351705
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypotonia, jaundice, and Chiari malformations: relationships to executive functions.
    Koziol LF; Barker LA
    Appl Neuropsychol Child; 2013; 2(2):141-9. PubMed ID: 23848246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Movement disorders and basal ganglia function].
    Dietrichs E
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood autism from the point of view of behavioral neurology.
    Maurer RG; Damasio AR
    J Autism Dev Disord; 1982 Jun; 12(2):195-205. PubMed ID: 7174608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding universe of disorders of the basal ganglia.
    Obeso JA; Rodriguez-Oroz MC; Stamelou M; Bhatia KP; Burn DJ
    Lancet; 2014 Aug; 384(9942):523-31. PubMed ID: 24954674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug treatment of hyperkinetic movement disorders.
    Fahn S
    Semin Neurol; 1987 Jun; 7(2):192-208. PubMed ID: 3332454
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical value of botulinum toxin in neurological indications.
    Ward AB; Molenaers G; Colosimo C; Berardelli A
    Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of athetosis.
    Lesný I
    Dev Med Child Neurol; 1968 Aug; 10(4):441-6. PubMed ID: 5681555
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
    Gordon MF; Diaz-Olivo R; Hunt AL; Fahn S
    Mov Disord; 1993 Oct; 8(4):484-8. PubMed ID: 8232358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders.
    Tilton AH
    J Child Neurol; 2003 Sep; 18 Suppl 1():S50-66. PubMed ID: 13677571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathogenetic therapy of spasticity].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):80-5. PubMed ID: 18697257
    [No Abstract]   [Full Text] [Related]  

  • 20. Motor disorders in basal ganglia disease.
    Marsden CD
    Hum Neurobiol; 1984; 2(4):245-50. PubMed ID: 6715209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.